Pyoderma gangrenosum: Retrospective evaluation of 20 cases Piyoderma gangrenozum: 20 olgunun retrospektif deǧerlendirilmesi


Serdar Z. A., YAŞAR Ş., Güneş P.

Turkderm Deri Hastaliklari ve Frengi Arsivi, cilt.45, sa.2, ss.83-87, 2011 (SCI-Expanded, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45 Sayı: 2
  • Basım Tarihi: 2011
  • Doi Numarası: 10.4274/turkderm.45.19
  • Dergi Adı: Turkderm Deri Hastaliklari ve Frengi Arsivi
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.83-87
  • Anahtar Kelimeler: Pyoderma gangrenosum, associated with diseases, treatment
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background and Design: The objective of this study is to examine the clinical properties, comorbid systemic diseases and the treatment protocols of the patients diagnosed with pyoderma gangrenosum (PG). Material and Method: Between 2003 and 2009 years, 20 patients diagnosed with pyoderma gangrenosum were evaluated in this study. The clinical properties, comorbid systemic diseases and the treatment protocols were examined retrospectively. Results: In a six-year period, 20 patients with PG (11 female and 9 male), ranging in age from 19 to 75 (mean age 45±16.39 years) were evaluated. Lesions had started as papule in 3 (16%) patients, as bullous in 1 (5%) patient, as erythematous plaque in 1 (5%) patient and as pustule in 15 (74%) patients. Whereas 14 (70%) patients had single lesion, the other patients had multiple lesions. The lesions were located at lower extremities in 14 (70%) patients most frequently, The most frequent comorbid disease in patients with pyoderma gangrenosum was inflammatory bowel diseases (colitis ulcerosa n: 4 and Crohn disease n: 2 total n: 6, 30%). The other comorbid diseases included vitiligo (n: 1, 5%), Behcet's disease (n: 1, 5%), hidradenitis suppurativa (n: 1, 5%), deep venous thrombosis and pulmonary embolism (n: 1, 5%), pangastritis (n: 1, 5%), acute renal failure (n: 1, 5%), systemic lupus erythematosus (n: 2, 10%) and iatrogenic immunosuppression (n: 1, 5%). Systemic corticosteroid therapy was the most common treatment (n=16, 80%). The treatment response was 100% in all patients. Conclusion: In our study, inflammatory bowel diseases were the most frequent comorbid diseases with pyoderma gangrenosum. Most of cases were as single lesions located in the lower extremities and the best treatment response was achieved by the administration of systemic corticosteroids.